DNA methylation in urological malignancies (review)

Area of Science:

• Urology
• Epigenetics
• Molecular Oncology

Background:

• DNA methylation alterations are observed in various urological malignancies.
• Three primary types of DNA methylation changes are identified: hypermethylation, hypomethylation, and loss of imprinting.

Purpose of the Study:

• To categorize urological tumors based on distinct DNA methylation alteration patterns.
• To explore the mechanisms and consequences of these alterations in cancer development.
• To assess the clinical utility of DNA methylation changes in cancer diagnosis and prognosis.

Main Methods:

• Categorization of tumors based on observed DNA methylation patterns (hypermethylation, hypomethylation, loss of imprinting).
• Analysis of the impact of DNA methylation alterations on gene expression and chromatin structure.
• Evaluation of potential clinical applications for detecting DNA methylation changes.

Main Results:

• DNA hypermethylation inactivates tumor suppressor genes in prostate, renal, and bladder cancers.
• Genome-wide hypomethylation is prominent in urothelial carcinoma and present in prostate cancer.
• Loss of imprinting is implicated in the development of embryonic tumors like Wilms' tumor and testicular cancer.
• Deranged methylation in bladder and prostate cancers involves fundamental disturbances in methylation establishment, leading to genomic instability.
• Hypermethylation is promising for cancer diagnosis, while hypomethylation may predict prognosis.

Conclusions:

• DNA methylation alterations are critical in urological carcinogenesis, influencing gene expression and genomic stability.
• Specific methylation patterns correlate with different urological tumor types.
• Targeting DNA methylation, particularly hypermethylated tumor suppressor genes, represents a promising therapeutic strategy.